New light therapy targets deadly brain tumors during surgery
NCT ID NCT05736406
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a treatment called photodynamic therapy (PDT) for people with a severe brain cancer called glioblastoma. Patients take a drug that makes cancer cells sensitive to light, then during surgery, a special light is used to destroy remaining tumor cells. The goal is to see if this approach is safe and tolerable when added to standard care. The trial involves 12 adults aged 18 to 75 with newly diagnosed glioblastoma.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
5-aminolevulinic acid hydrochloride (Pentalafen®) with light therapy (Heliance® device)
What this could lead to
If successful, this could lead to a new treatment option that improves survival for people with glioblastoma, a severe brain cancer.
What could go wrong
This is an early-phase trial with only 12 participants, so results may not apply to everyone. The treatment involves brain surgery and light therapy, which carries risks like infection or brain swelling.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU De Lille, Hôpital Roger Salengro
Lille, 59037, France
-
UPMC Hillman Cancer center
Pittsburgh, Pennsylvania, 15213, United States